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Background: Occupational exposure to live meningococci can potentially cause invasive meningococcal disease in
laboratory staff. While, until recently, immunization with quadrivalent polysaccharide vaccine represented one
cornerstone of protection, data on long-term persistence of antibodies in adults remain scarce.
Methods: We analyzed the relationship of antibody levels and time following quadrivalent polysaccharide
vaccination (MencevaxW ACWY, GlaxoSmithKline) in a cross-sectional sample of 20 laboratory workers vaccinated at
ages between 16.4 to 40.7 years from Germany. Sera were obtained 0.4 to 158.5 (median 35.3) months after
vaccination. At the time of sampling, laboratory workers had been regularly exposed to meningococci for periods
between 3.2 to 163.8 (median 41.2) months. Serum bactericidal assay (SBA) with rabbit complement and a
microsphere-based flow analysis method were used to determine bactericidal titers and concentrations of IgG,
respectively, against serogroups A, C, W135, and Y. Decay of antibodies was modeled using linear regression.
Protective levels were defined as SBA titers ≥ 8.
Results: Half-lives of SBA titers against serogroups A, C, W135, and Y were estimated at 27.4, 21.9, 18.8, and
28.0 months, respectively. Average durations of protection were estimated at 183.9, 182.0, 114.6, and 216.4 months,
respectively. Inter-individual variation was high; using lower margins of 95% prediction intervals, minimal durations
of protection against serogroups A, C, W135 and Y were estimated at 33.5, 24.6, 0.0, and 55.1 months, respectively.
The proportion of staff with protective SBA titers against W135 (65.0%) was significantly lower than proportions
protected against A (95.0%), C (94.7%), and Y (95.0%). Consistently, geometric mean titer (97.0) and geometric mean
concentration of IgG (2.1 μg/ml) was lowest against serogroup W135. SBA titers in a subset of individuals with
incomplete protection rose to ≥ 128 (≥ 8 fold) after reimmunization with a quadrivalent glycoconjugate vaccine.
Conclusions: The average duration of protection following immunization with a quadrivalent polysaccharide vaccine
in adults was≥ 115 months regardless of serogroup. A substantial proportion (approximately 23% according to our
decay model) of adult vaccinees may not retain protection against serogroup W135 for five years, the time suggested
for reimmunization.
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Neisseria meningitidis, commonly known as the menin-
gococcus, is a Gram-negative bacterium that colonizes
the pharyngeal mucosa of approximately 10% of humans
in an age-dependent manner [1]. In rare cases, it causes
potentially deadly invasive disease in the form of menin-
gitis or sepsis in previously healthy individuals. Most
cases appear in infants and adolescents [2], but adults over
the age of 25 are also affected. According to their polysac-
charide capsule, meningococci can be distinguished into
twelve serogroups [3]. Globally, most cases of invasive dis-
ease are caused by serogroups A, B, C, W135, X, and Y.
To date, licensed vaccines consisting of polysaccharide or
glycoconjugate-formulations exist for the prevention of
disease by serogroups A, C, W135, and Y.
Laboratory staff working with live cultures of menin-
gococci are at a potentially increased risk of contracting
disease. A study based on cases from the USA con-
trasted an attack rate of 13/100,000 among microbiolo-
gists between 1996 and 2001 to the incidence rate of
0.2/100,000 among adults in general [4]. Similarly, a UK
analysis claimed that laboratory workers had a 184-fold
increased risk of disease compared with the background
population [5]. As lethality in documented laboratory-
acquired cases reaches 50%, prevention to exposure of
droplets or aerosols containing N. meningitidis by the
use of biological safety cabinets is critical [4]. A further
control measure is vaccination of staff, as 44% of cases
are preventable by presently licensed vaccines [4]. Even
though the recent death of a laboratory worker sadly un-
derscores the current lack of vaccine preventability
against serogroup B [6], the continuing importance of
adequate immunization is emphasized by several reports
of vaccine-preventable cases [7-9] that were published
after the survey by Sejvar et al. [4].
Currently authorities in several countries including the
Centers of Disease Control and Prevention (CDC), USA,
Department of Health (DoH), UK, and Robert-Koch-Insti-
tute (RKI), Germany, recommend primary immunization
of laboratory workers exposed to meningococci with
quadrivalent glycoconjugate vaccine [10-12]. Nevertheless,
a presumably large proportion of presently employed
personnel received primary immunization with until re-
cently recommended polysaccharide vaccine. DoH [10]
and CDC [13] recommend revaccination of adults who
had received a polysaccharide vaccine, if at continued risk,
after five years. To our knowledge, recommendations re-
garding travelers do not differ regarding periods of
reimmunization.
Serum-bactericidal antibody (SBA) titers of ≥ 8 using
rabbit complement are regarded as the most practical cor-
relate for protection against serogroup C disease and have
since been applied to serogroup A, Y and W135 [14].
Levels of immunoglobulin, specifically concentrationsexceeding 2 μg/ml, were only found useful for the predic-
tion of protection against serogroup A [15]. It is the per-
sistence of SBA after vaccination that warrants protection
against invasive disease rather than immune memory,
given that the rise in SBA after boosting is too slow to pre-
vent invasive disease [16,17]. While soon after intro-
duction of polysaccharide vaccines several reports have
detailed the rapid decline of antibody levels after
immunization in children [18,19], the length of persist-
ence in adults has not been studied extensively. To our
knowledge, only one report has investigated the duration
of antibody response after immunization of adults with
quadrivalent meningococcal polysaccharide targeting se-
rogroups A, C, W135, and Y, suggesting persistence of
bactericidal antibodies against serogroup C for up to ten
years after vaccination [20]. Nevertheless, bactericidal ac-
tivity was not followed up in that study for serogroups A,
W135, and Y.
Our report documents antibody response directed against
A, C, W135, and Y in a cross-sectional sample of sera
obtained from 20 laboratory workers previously vaccinated
once with a quadrivalent polysaccharide vaccine. The aim
of our analysis is to describe and model the relationship
of antibody levels and time passed since immunization.
Methods
Sera
A cross-sectional sample of sera from 20 laboratory staff
employed at the Institute for Hygiene and Microbiology,
University of Wuerzburg, Germany, was analyzed. Sera
were collected between June 2008 and December 2010
and frozen at −80°C until analysis. Staff were eligible to
participate if they had occupational exposure to live cul-
tures of Neisseria meningitidis in the year before sampling
and had been vaccinated once with a polysaccharide vac-
cine by the occupational health physician. Of 20 eligible
laboratory workers all agreed to participate. Participants
were informed that the analysis was part of an internal
quality control in occupational health with the aim to
identify individuals not possessing protective SBA titers.
All participants had been immunized only once with
MencevaxW ACWY (GlaxoSmithKline GmbH & Co.,
Munich, Germany), a meningococcal vaccine containing
50 μg each of serogroup A, C, W135, and Y capsular poly-
saccharide. The exact dates of vaccination were verified
by examining the vaccination booklets of the partici-
pants. Serum samples were obtained 0.4 to 158.5 (median
35.3) months after vaccination and age of employees at
vaccination ranged from 16.4 to 40.7 (median 25.6) years
(Additional file 1: Table S1). Twelve of 20 (60%) partici-
pants were female. As part of their laboratory occupation
employees were regularly exposed to live N. meningitidis
for time periods between 3.2 to 163.8 months (median
41.2, interquartile range 28.7 to 74.1) before donating
Table 1 Geometric means of antibody levels against
serogroups A, C, W135, and Y
A C W135 Y
SBA GMT 256.0 598.8 97.0 531.0
≥ 8 (%) 19 (95.0%) 18 (94.7%) 13 (65.0%) 19 (95.0%)
IgG GMC (μg/ml) 17.4 4.9 2.1 2.4
≥ 2 μg/ml (%) 20 (100.0%) 13 (68.4%) 8 (40.0%) 8 (40.0%)
SBA: serum bactericidal assay; IgG: Immunoglobulin G; GMT: geometric mean
titer; GMC: geometric mean concentration in μg/ml.
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group C was excluded for one individual (participant no.
17, Additional file 1: Table S1), who was additionally vac-
cinated with NeisVac-CW (Baxter Deutschland GmbH,
Unterschleißheim, Germany), a glycoconjugate vaccine
against serogroup C, six months after receiving polysac-
charide vaccination. All participants received written
statements regarding their level of protection. In addi-
tion, all participants signed written consents agreeing to
the publication of their data in anonymized form in ac-
cordance with the Ethics Committee of the University of
Wuerzburg.
Serum bactericidal antibody activity
SBA was assessed with baby rabbit complement (Pel-
FreezW Biologicals, AR, USA) using the method previously
described [21], except that after incubation with serum,
bacterial suspensions were dropped and tilted onto sheep
blood plates (bioMérieux, Nürtingen, Germany) and grown
overnight at 35°C and 5% CO2. The reference strains for
serogroups A, C, W135, and Y were F8238, C11,
M01.240070, and M00.242975, respectively. Colonies were
counted with the ProtoCOL device (Synbiosis, Cambridge,
UK). SBA titers were expressed as the reciprocal of the
final serum dilution giving ≥ 50% killing at 60 minutes.
Titers ≥ 8 were regarded as protective [14]. Titers < 4 were
assigned a value of 2.
Determination of IgG concentrations
Concentrations of IgG directed against capsular polysac-
charide of serogroups A, C, W135, and Y were deter-
mined using a microsphere-based flow analysis method
[22]. Sera were titrated against the International menin-
gococcal standard reference serum CDC 1992 [23].
Statistical analyses
To analyze the relationship between SBA titers or IgG
concentrations and time after vaccination the following
simplifying assumptions were used: 1) antibodies were
expected to decay following a simple exponential model,
described by L = L0 · e
km, where L represents antibody
level mmonths after attaining L0, L0 is the plateau level
after vaccination, and k stands for the first-order rate
constant; 2) we premised that plateau concentrations
(L0) were attained 10 days after vaccination in each indi-
vidual, as described in a Dutch study detailing daily
changes in antibody levels in adults after primary
immunization [16], after which decline according to
above function set in. The value of L0 and k were esti-
mated using linear regression of log-transformed titers
or concentrations according to log(L) = a+ km, where ea
equals L0 and k can be conveniently extracted from the
slope of the fitted line. Also, we assumed log-normal dis-
tribution of antibody levels. We chose months astemporal units, whereby one month was equivalent to
30.42 days. Half-life λ in months was calculated as λ ¼
log 0:5ð Þ
k . Differences in geometric mean titers (GMT) or
concentrations (GMC) between serogroups were assessed
using within-subjects ANOVA of log-transformed levels.
The Friedman test, a nonparametric analogue, was add-
itionally completed, if log-transformed data failed the
Shapiro-Wilk test for normality (i.e. p < 0.05). Differences
in the proportions of individuals with protective SBA titers
(≥ 8), or IgG concentrations ≥ 2 μg/ml against the analyzed
serogroups were evaluated with Cochran’s Q test. We used
Pearson’s product moment correlation coefficient to de-
scribe association between log-transformed IgG concen-
trations and SBA titers. Linear regression was performed
with the program R [24], version 2.14.1. Prediction inter-
vals for fitted log-transformed antibody levels were gener-
ated with R’s built-in function “predict.lm”; percentiles of
prediction intervals were computed assuming a symmetric
distribution of forecast antibody levels centered on the
value fitted by linear regression (equal to 50th percentile).
Results
Serum bactericidal antibody titers
SBA GMTs differed significantly across serogroups, as
shown by within-subjects ANOVA of log-transformed
values (p = 0.006; Table 1). The proportion of individuals
within our sample presumably protected against disease,
as inferred by the rate of sera with titers ≥ 8, differed sig-
nificantly across serogroups (Cochran’s Q: 13.2 on 3 de-
grees of freedom, p = 0.004); protection against serogroup
W135 was lowest with 65.0%, while protection exceeded
94.7% for all other serogroups (Table 1).
Decay models
SBA titers against all serogroups significantly decreased
with time (Figure 1), evidenced by negative slopes in lin-
ear regression (Table 2). Log-transformed SBA titers and
residuals of linear models showed no evidence against
normal distribution. W135 SBA titers showed the lowest
estimated initial value (L0 = 541.5) and strongest decay
(k = −0.037); nevertheless, estimated parameters for other
serogroups (A, C, and Y) were within 95% confidence in-
tervals of W135’s L0 (73.0 to 4,016.4) and k (−0.070 to –
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Figure 1 Kinetics of serum bactericidal antibody titers against meningococci of serogroups A, C, W135, and Y. Obs: observed titers,
D: mean decay, PI: 95% prediction interval, PT: protective threshold, 5Y%: cropped contour line representing percentile of prediction interval
below protective threshold five years after vaccination.
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By extrapolation of the fitted line, average SBA titers for
serogroups A, C, W135, and Y were expected to fall
below the protective threshold of 8 at 183.9, 182.0, 114.6,
and 216.4 months, respectively, after attaining L0. To ac-
count for high inter-individual variation, we used the
crossing points of the lower margins of 95% prediction
intervals with horizontal lines at the putative protective
SBA titre of ≥ 8 to estimate probable minimal durations
of protection (Figure 1): except for W135 (0.0 months),
values surpassed 24 months after reaching L0 (A: 33.5, C:
24.6, Y: 55.1). Population estimates of the proportion of
adults not protected after 5 years, the period suggested
for reimmunization [10,13], were computed using the
percentile of the models’ prediction intervals at 60 -
months intersecting the protection level: intervals equalTable 2 Estimated parameters of the decay of serum-bacterici
vaccination
Serogroup L0 (CI)
A 834.1 (219; 3,176.5)
C 2,522.2 (442.2; 14,387.8)
W135 541.5 (73.0; 4,016.4)
Y 1,687 (413.3; 6,886.5)
L0: titer after vaccination, CI: 95% confidence interval, k: first-order rate constant, λ:or below the 5th, 5th, 23rd, and 3rd percentile
corresponded to titers < 8 for serogroups A, C, W135,
and Y, respectively (Figure 1).
Concentration of IgG
Linear regression of log-transformed concentration by
time (months) predicted negative slopes for all sero-
groups (A: -0.010, C: -0.013, W135: -0.017, Y: -0.011),
suggesting slight decay with time (Figure 2). Nevertheless,
slopes were not significantly different from zero for any
serogroup (Figure 2; A: p = 0.056, C: p = 0.081, W135:
p = 0.122, and Y: p = 0.289). Consistent with SBA titers,
however, both the GMC and fitted slope was lowest for
W135 (2.1 μg/ml and −0.017, respectively). IgG GMCs dif-
fered significantly between serogroups according to within-
subjects ANOVA of log-transformed values (p < 0.001). Asdal antibody titers after meningococcal polysaccharide
k (CI) λ (CI)
−0.025 (−0.048; -0.003) 27.4 (14.5; 248.9)
−0.032 (−0.061; -0.002) 21.9 (11.3; 343.7)
−0.037 (−0.070; -0.003) 18.8 (9.8; 224.1)
−0.025 (−0.048; -0.001) 28.0 (14.3; 641.6)
half-life in months (derived from k).
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Figure 2 Kinetics of serum IgG concentrations against capsular polysaccharides of meningococcal serogroups A, C, W135, and Y. Obs:
observed concentration; Trend: fitted line of linear models (slopes were not significantly different from zero for any of the serogroups); GMC:
geometric mean concentration.
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Y showed evidence against normal distribution, the Fried-
man test was additionally performed, which confirmed
non-random distribution of concentrations across sero-
groups (p < 0.001). This was not an effect of the low con-
centration against W135 (2.1 μg/ml), which was close to C
(4.9 μg/ml) and Y (2.4 μg/ml), but due to the high GMC
of antibodies directed against A (17.4 μg/ml). Similarly,
the significant difference in the proportion of individuals
with concentrations equal or above 2 μg/ml (Cochran’s Q:
21.2, 3 d.f., p < 0.001) was a result of the high concentra-
tion of IgG against A: thus, 20 of 20 employees with re-
gard to A, yet only 13, 8, and 8 with regard to C, W135,
and Y, respectively, had concentrations surpassing 2 μg/ml
(Table 1).
Correlation of serum bactericidal antibody titers and IgG
concentrations
A significant correlation of log-transformed SBA titers
and IgG concentrations was demonstrated for sero-
groups C and W135, with coefficients of 0.670 (95% CI
0.356 to 0.874) and 0.581 (95% CI 0.186 to 0.814), re-
spectively. In contrast, there was no conclusive evidence
for association between SBA titers and IgG concentra-
tions directed against serogroup A or Y with correlationcoefficients of 0.382 (95% CI −0.073 to 0.705) and 0.094
(95% CI −0.364 to 0.515), respectively. Of note, the value
for Y was barely above zero and significantly lower than
estimates for C and W135.
Serum bactericidal antibody titers after immunization
with conjugate vaccine
Six of 20 participants (30%) showed insufficient protection
against at least one of the serogroups tested (Additional file
1: Table S1) and were therefore offered vaccination with a
quadrivalent glycoconjugate vaccine (MenveoW, Novartis
Vaccines & Diagnostics GmbH, Marburg, Germany). Of
four staff continuing to be employed at the research facility
in Wuerzburg, three agreed to be revaccinated. Sera of
these individuals were obtained four weeks after vaccin-
ation and assayed for SBA: all revaccinated individuals de-
veloped titers ≥ 128, corresponding to at least 8-fold
increases compared to pre-boost values, against A, C,
W135, and Y (Table 3).
Discussion
In contrast to glycoconjugate vaccines the immune re-
sponse generated by polysaccharide vaccines is generally
poorly immunogenic in infants, does not elicit a memory
response, and produces antibodies of lower avidity with
Table 3 Serum-bactericidal antibody titers four weeks
after application of a booster dose with a quadrivalent
conjugate vaccine
PN Serum bactericidal antibody titers
A C W135 Y
17 4,096 (16) 8,192 (−) 128 (32) 4,096 (1,024)
18 512 (256) 512 (8) 8,192 (4,096) 8,192 (1,024)
19 8,192 (128) 2,048 (128) 2,048 (1,024) 16,384 (64)
Titers are from three laboratory workers with low antibody titers. Parentheses
contain fold increases compared to pre-boost titers (see Additional file 1: Table S1).
PN: participant number, ‘-‘: prevaccination value excluded from the sample.
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[25]. Additionally, several polysaccharide vaccines in-
cluding polysaccharide C [26] have been shown to elicit
hyporesponsiveness, i.e. diminished immune response
after booster compared to primary vaccination. The pro-
tective effect of meningococcal polysaccharide vaccines
is strongly age dependent. Early clinical studies have
shown inferior protection from invasive disease after
polysaccharide A vaccination in children < 4 years [27],
and no protection in recipients of polysaccharide C
below 24 months of age [28]. While total antibody con-
centrations after polysaccharide C vaccination fails to ex-
plain higher susceptibility in immunized infants [29], the
SBA assay, specifically a titer of ≥ 8 when measured with
rabbit complement, is currently the most practical method
for the prediction of immunity after vaccination [14]. It
has superseded correlates based on antibody concentra-
tions alone, e.g. an earlier proposal suggesting protection
at concentrations of IgG ≥ 2.0 μg/ml [15].
While short-term qualitative and quantitative charac-
teristics of the immune response to meningococcal poly-
saccharide vaccines have been extensively studied, less
information is available on long-term effects. Antibody
levels against serogroup C rapidly wane in infants [18,29]
and seem to persist less than 4 years in children above the
age of two [19]. Persistence of antibody levels in adults
seems to last considerably longer, but very few studies
have been published detailing long-term protection in
older age groups: Zangwill et al. described elevated SBA ti-
ters to serogroup C (measured with rabbit complement)
in adult vaccinees even after ten years [20].
In the present survey we have used a convenience sam-
ple of 20 individuals vaccinated only once with polysac-
charide A, C, W135, and Y to analyze the association of
observed antibody levels with time since immunization.
Our analyses suggest that average durations of protective
SBA titers to serogroups A, C, W135, and Y exceed 115
months. Previously published data for serogroup C may
serve to validate the long-term predictive ability of our ex-
ponential model of decay: Zangwill et al. describe a rise of
SBA titers from a pre-vaccination level of 13.6 to 1111.9
after vaccination. Using parameters 1111.9 and −0.032(Table 2) as parameters L0 and k, respectively, our model
predicts a SBA titer of 23.9 after 120 months (calculated
as exp(log(1111.9) - 0.032 · 120)). This value is slightly
below the observed value of 70 [20], which, assuming our
model is valid, would correspond to a rate constant
−0.023 (= log(70/1111.9)/120) and thus to a deviation of
28% regarding parameter k. Despite this small error, our
model reproduces the original observation that titers after
10 years are still higher than pre-vaccination levels. We
have found no further studies following up SBA levels ex-
ceeding five years after polysaccharide vaccination.
Moreover, we detailed the substantial inter-individual
variability of both SBA titers and IgG levels directed
against reference strains of targeted serogroups. The es-
timated minimal duration for W135 (0 months) suggests
that some vaccinees may not attain lasting protection
against this serogroup at all. Also, our model of decay for
titers against W135 forecasts that a substantial part
(approximately 23%) of vaccinees loses protection against
this serogroup by 5 years, the time recommended for re-
vaccination [10,13]. The lower level of protection against
W135 compared to other serogroups was further sug-
gested by the significantly lower proportion of protective
titers (65%) in our sample. Also, the quantification of IgG
revealed that GMC reacting with polysaccharide W135
was the lowest (2.1 μg/ml) among the serogroups ana-
lyzed. On the other hand, our decay models predict that
minimal durations of protection against serogroups A, C,
and Y appear to exceed 24 months and only minor pro-
portions (≤ 5%) probably lose protection within 5 years.
As absolute risk for acquiring meningococcal disease for
laboratory workers is low [4], only few case reports exist
that could corroborate or refute suggested minimal dura-
tions of protection. Of those, we found only one report
that contained previous vaccination history with polysac-
charide vaccine. It describes infection of a laboratory
worker 67 months after application of meningococcal A +
C polysaccharide vaccine (Sanofi Pasteur MSD) caused by
a serogroup A meningococcal strain [9]. As our model
forecasts a probability of > 5% of missing protection after
this interval, it is plausible that the laboratory worker was
not immune at the time of exposure.
In contrast to SBA titers, we could not detect a signifi-
cant decay of IgG levels with time. This is most likely
due to the small power of our analysis to detect decays
with slopes barely differing from zero. Zangwill et al.,
using a sample of 40 adults, described a decrease of total
anti-capsular antibody concentration against serogroups
A and C 10 years after vaccination; nevertheless, they
noted that it was smaller than that seen in SBA titers
against serogroup C [20].
GMCs differed significantly across serogroups with GMC
against serogroup A considerably higher (17.4 μg/ml) than
that of other serogroups. It is unlikely, however, that
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frequently show high baseline levels against this se-
rogroup. Levels of IgG in unimmunized individuals were
1.5 μg/ml and even 17.5 μg/ml in a study encompassing
unimmunized individuals from North America and Sudan,
respectively [30]. The reasons for high pre-vaccination
concentrations of IgG and other immunoglobulin classes
remain unclear, yet it is likely that several commensal bac-
teria including Escherichia coli [31] and Bacillus pumilus
[32] give rise to cross-reacting antibody populations. Their
role in bactericidal immunity, however, seems to be minor
[30]. Although we cannot confirm it for our sample given
the lack of pre-vaccination samples, it is probable that ob-
served high concentrations of IgG against serogroup A are
a corollary of high pre-existing levels rather than excep-
tional immunogenicity of serogroup A polysaccharide
within the administered vaccine.
Several authors have investigated the correlation of
SBA titers and concentrations of IgG after meningococ-
cal polysaccharide vaccination. Maslanka et al. found a
positive correlation for all investigated age groups after
vaccination with serogroup C polysaccharide, noting that
correlation was lowest in 1 year olds with a correlation
coefficient of 0.34 [29]. Granoff et al. observed increased
correlation of high-avidity antibodies with SBA titers after
serogroup C polysaccharide immunization and concluded
that low-avidity, probably non-functional antibodies de-
crease correlation [33]. Also, moderate correlations be-
tween IgG and SBA titers of 0.56 and 0.37 were found in
adults [34] and toddlers [35] after vaccination with
serogroup A polysaccharide. Moreover, several groups
reported no correlation between antibody concentrations
and SBA titers against serogroup C in non-immunized
individuals [33,36]. We found significant associations be-
tween antibody concentrations and SBA titers only against
serogroups C and W135. For A and Y, however, it seems
that antibody concentrations contribute little to the ex-
planation of protection. While in the case of serogroup A
this may be due to high and varying levels of cross-
reactive antibodies, the reason for a missing association in
serogroup Y remains elusive. In contrast to A the correl-
ation coefficient in Y is so low that it seems unlikely that
our failure to determine a positive association is due to
low power of our sample.
Finally, we report the considerable proportion of incom-
plete protection (30%) in a convenience sample of labora-
tory workers. As recommended by several authorities
including the RKI [12], polysaccharide-conjugate vaccine
should be used to reinforce immunization and to avoid
development of hyporesponsiveness. We have shown for a
small subset, that, as expected, revaccination with conju-
gate vaccine is indeed effective in restoring SBA titers.
Our survey has several limitations. Firstly, our sample
size is small with 20 individuals tested, which is due tothe low availability of adult individuals who have been
immunized once with meningococcal polysaccharide
vaccine. This entails that our power to detect differences
in the kinetics of antibody responses against different
serogroups is small. Secondly, our sample is cross-
sectional in nature, which leads to impaired temporal
resolution in the description of decay. A consequence is
that we are unable to test whether more elaborate
models would provide a better fit to observed data; e.g.
Zangwill et al. describe a decrease of titers by 94% in the
first two years, which is considerably higher than a de-
crease of 54% predicted by our exponential model. Fi-
nally, we cannot say whether all individuals showed
adequate response to the vaccine, as we do not have
pre-vaccination samples. Judging from estimated L0
values, however, most participants will have attained
SBA titres ≥ 8 after vaccination. In spite of these limita-
tions, we have been able to correctly reproduce major
long-term observations.
In summary, we present data on the long-term
persistence of antibodies after meningococcal polysacchar-
ide vaccination in adults, which represents an under-
researched topic.Conclusions
Average duration of protection in adults immunized
with meningococcal polysaccharide vaccine reaches ten
years or more. Due to considerable inter-individual vari-
ability protection falls below the average estimate in a
substantial proportion of adults immunized with poly-
saccharide formulations. Specifically, immunity against
serogroup W135 may last less than five years, the period
suggested by CDC [13] and UK’s Department of Health
[10] for reimmunization, for approximately 23% of vacci-
nees. Thus, presented observations may contribute to re-
consideration of the presently recommended periods for
revaccination of adults at risk for occupational infection.Additional file
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